Biomimiq provides services using both healthy and diseased in vitro human skin equivalents (HSEs) for animal-free compound screening and safety testing services and for co-development activities. Biomimiq’s HSEs are used in new product development and substantiation of product claims in cosmetic, food and pharmaceutical industries, but also in fundamental research within the worldwide academic field of experimental dermatology. These HSEs enable genomic, proteomic and drug development research that is not possible with traditional, unrepresentative or even unavailable animal models, two-dimensional monolayer cell cultures or clinical test procedures. Uniquely, all of Biomimiq’s in vitro HSEs are fully customizable to meet both the scientific and commercial demands of the customer. Biomimiq's in vitro skin models are currently only used in services and are not available for individual sale.
Biomimiq is a start-up business which originated from the research unit of the Department of Dermatology of the Leiden University Medical Centre (LUMC) in Leiden, the Netherlands. Biomimiq’s portfolio of human skin equivalents (HSEs) is based on more than 25 years of skin tissue engineering captured in over 200 peer-reviewed scientific papers. The academic research group has its roots in the early 1980’s, under the inspiring leadership of dr. Maria Ponec. From 2005, the group was successfully continued by dr. Abdoelwaheb El Ghalbzouri. For the past decade, this HSE research group successfully effectuated commercial service contracts and co-development activities, in addition to fundamental and applied scientific activities. Today, expansion of these commercial endeavours is secured by an exclusive licensing agreement on the HSE technology from the LUMC to Aeon Astron Europe B.V. As such, Biomimiq is a division of Aeon Astron Europe B.V.
International biotechnology company
Aeon Astron Europe B.V. is an international biotechnology company located in Leiden, the Netherlands. It is a wholly owned subsidiary of the Taiwanese company BOBC (Body Organ Biomedical Corporation), which was set up in 2007 and whose stock is currently listed at the Taiwan Gretai securities market. Aeon Astron Europe B.V. is dedicated to discovering, developing, producing and marketing state‐of‐art regenerative solutions to save lives as well as to restore and improve health. This is in synergy with the potential of Biomimiq’s in vitro HSEs in the development of new therapeutics and skin tissue regeneration solutions in humans. The product pipeline of Aeon Astron Europe B.V. expands across the fields of dermatology, ophthalmology, dentistry, orthopaedics and general and plastic surgery.